Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of Medicine, Harvard Medical School elaborates on the efficacy and safety of combination eribulin and pembrolizumab in metastatic breast cancer.
Efficacy and Safety of Combination Eribulin + Pembrolizumab
